• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.

作者信息

Alva-Ruiz Roberto, Truty Mark J

机构信息

Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.

出版信息

Ann Surg Oncol. 2022 Mar;29(3):1592-1593. doi: 10.1245/s10434-021-11019-5. Epub 2021 Oct 27.

DOI:10.1245/s10434-021-11019-5
PMID:34705142
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8810449/
Abstract
摘要

相似文献

1
ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer.ASO作者反思：新辅助化疗转换：优化胰腺癌新辅助治疗顺序
Ann Surg Oncol. 2022 Mar;29(3):1592-1593. doi: 10.1245/s10434-021-11019-5. Epub 2021 Oct 27.
2
ASO Author Reflections: The Role of Neoadjuvant Chemotherapy in Invasive Intraductal Mucinous Neoplasms of the Pancreas.ASO作者反思：新辅助化疗在胰腺浸润性导管内黏液性肿瘤中的作用
Ann Surg Oncol. 2024 May;31(5):2967-2968. doi: 10.1245/s10434-024-15002-8. Epub 2024 Mar 14.
3
ASO Author Reflections: Is Neoadjuvant Chemotherapy Associated with Acceptable Short-Term Outcomes for Pancreatic Cancer?ASO作者反思：新辅助化疗与可接受的胰腺癌短期预后相关吗？
Ann Surg Oncol. 2021 Apr;28(4):1906-1907. doi: 10.1245/s10434-020-09472-9. Epub 2021 Jan 2.
4
ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement.ASO作者反思：关于新辅助化疗治疗伴有动脉侵犯的可切除边缘胰腺癌的新证据
Ann Surg Oncol. 2023 Jan;30(1):203-204. doi: 10.1245/s10434-022-12584-z. Epub 2022 Sep 21.
5
ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal.ASO作者反思：可切除边缘和局部晚期胰腺癌的化疗方案——手术是关键。
Ann Surg Oncol. 2023 Jul;30(7):4429-4430. doi: 10.1245/s10434-023-13484-6. Epub 2023 Apr 19.
6
ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?ASO作者反思：单纯化疗用于胰腺癌的全新辅助治疗？
Ann Surg Oncol. 2024 Sep;31(9):6203-6204. doi: 10.1245/s10434-024-15660-8. Epub 2024 Jun 22.
7
ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.ASO作者反思：胰腺癌新辅助化疗减轻了省略辅助化疗的有害影响。
Ann Surg Oncol. 2021 Jul;28(7):3808-3809. doi: 10.1245/s10434-020-09487-2. Epub 2021 Jan 21.
8
ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone for the PREOPANC-4 Trial.美国外科医师学会作者反思：荷兰诱导化疗后局部晚期胰腺癌手术的全国性经验：PREOPANC-4试验的垫脚石
Ann Surg Oncol. 2024 Apr;31(4):2658-2659. doi: 10.1245/s10434-023-14704-9. Epub 2023 Dec 13.
9
ASO Author Reflections: What is the Optimal Method for Predicting a Response to Neoadjuvant FOLFIRINOX Chemotherapy for Pancreatic Cancer?ASO作者反思：预测胰腺癌新辅助FOLFIRINOX化疗反应的最佳方法是什么？
Ann Surg Oncol. 2024 Feb;31(2):1364-1365. doi: 10.1245/s10434-023-14658-y. Epub 2023 Dec 10.
10
ASO Author Reflections: Does Adjuvant Therapy Confer a Survival Benefit in Patients Receiving Neoadjuvant Chemotherapy for Pancreatic Cancer? A CA19-9 Analysis.ASO作者反思：辅助治疗对接受新辅助化疗的胰腺癌患者有生存获益吗？一项CA19-9分析。
Ann Surg Oncol. 2020 Oct;27(10):3961-3962. doi: 10.1245/s10434-020-08542-2. Epub 2020 May 5.

引用本文的文献

1
Recent Advances in RNA Interference-Based Therapy for Hepatocellular Carcinoma: Emphasis on siRNA.基于 RNA 干扰的肝细胞癌治疗的最新进展：重点是 siRNA。
Cell Biochem Biophys. 2024 Sep;82(3):1947-1964. doi: 10.1007/s12013-024-01395-6. Epub 2024 Jul 10.
2
Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma.胰腺腺癌新辅助治疗的手术考量
Cancers (Basel). 2023 Aug 19;15(16):4174. doi: 10.3390/cancers15164174.

本文引用的文献

1
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.局部进展期/交界可切除胰腺癌的新辅助化疗转换。
Ann Surg Oncol. 2022 Mar;29(3):1579-1591. doi: 10.1245/s10434-021-10991-2. Epub 2021 Nov 1.
2
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.吉西他滨/白蛋白紫杉醇解救治疗 FOLFIRINOX 早期失败后局部晚期或边缘可切除胰腺腺癌患者的获益。
Pancreas. 2019 Jul;48(6):837-843. doi: 10.1097/MPA.0000000000001345.
3
Resection of Locally Advanced Pancreatic Neoplasms after Neoadjuvant Chemotherapy with Nab-Paclitaxel and Gemcitabine following FOLFIRINOX Failure.在FOLFIRINOX方案失败后，使用白蛋白结合型紫杉醇和吉西他滨进行新辅助化疗后对局部进展期胰腺肿瘤进行切除。
Case Rep Gastroenterol. 2017 Aug 4;11(2):422-427. doi: 10.1159/000478722. eCollection 2017 May-Aug.
4
Significance of pathologic response to preoperative therapy in pancreatic cancer.术前治疗病理反应对胰腺癌的意义。
Ann Surg Oncol. 2011 Dec;18(13):3601-7. doi: 10.1245/s10434-011-2086-4. Epub 2011 Sep 27.